Newsmeme!
Discover News you didn't know existed
1 What is it? This painful, progressive condition, also called median nerve entrapment, occurs when the median nerve, which runs from the forearm into the hand, becomes pressed or squeezed at the wrist. It's more common in women and it affects up to 10 percent of the population.
QUEBEC CITY, QUEBEC-- - Bioxel Pharma Inc. , a leading manufacturer of taxane active pharmaceutical ingredients and developer of targeted oncology drugs, today announced its results for the second quarter ended June 30, 2008.
Pharmos Corporation today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey.
Cedarville University has been ranked as one of the best colleges in the Midwest.
(ARA) - Of the 10 million Americans with osteoporosis, 80 percent are women, and having a mother with osteoporosis puts a daughter particularly at risk for fractures.
Westbound lanes of Interstate 80 were closed Wednesday night at 60th Street due to an accident. Authorities said the driver of a Chevy Camaro entered I-80 from the 84th Street ramp at a high rate of speed around 6:30 p.m.
Genmab A/S announced today results for the six month period ended June 30, 2008. During this period, Genmab reported the following results:
Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it has been awarded a 2-year, $3.4 million grant from the United States Department of Defense(1) to develop technology to advance vaccine research and development. Under the grant, Maxygen will continue development of ParallelaVax(TM) technology for rapid generation of ...
REDWOOD CITY, Calif.----Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that it has been awarded a 2-year, $3.4 million grant from the United States Department of Defense1 to develop technology to advance vaccine research and development.
Genmab A/S (OMX: GEN) announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year. "Genmab and GSK have worked diligently to expand the ofatumumab development program to maximize the value of the antibody for patients and shareholders since our collaboration began," said Lisa N. Drakeman, Ph.D.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |